Original Article introduCtion For patients with end-stage renal disease, kidney transplantation has been described as optimal treatment. In India, much advancement has been made in the area of kidney transplantation in the past 45 years. In this highly populated developing country, approximately 151-232 per million population are in need of kidney transplantation.
Transplant biopsy is an invasive procedure with major complications comprising hemorrhage requiring blood transfusions, intra-arterial embolization, or surgical intervention. [6, 7] Apart from complications, biopsy adequacy is also an important aspect. "Adequate" specimen is defined as a biopsy with ten or more glomeruli and at least two arteries, and for a minimal sample, at least seven glomeruli and one artery are needed. [8] The characteristics of a successful procedure are not only safety and adequacy but also its diagnostic yield.
In this study, we analyzed indications, complications, and adequacy of renal allograft biopsies performed at our center. We also assessed whether histopathological diagnosis provided by kidney biopsy matched the clinical provisional diagnosis and what impact histopathological diagnosis made on line of treatment.
mEthodology
This retrospective analysis included all patients who underwent percutaneous renal allograft biopsies from January 1, 2012, to December 31, 2017, at the Department of Nephrology and Renal Transplant, Sawai Man Singh Medical College, Jaipur, Rajasthan, India. Data were obtained from the departmental renal transplant patient database and from the patients' records. A detailed history was taken regarding basic disease, pretransplant and posttransplant course, and indication of biopsy from each patient. All patients had laboratory blood tests including complete blood count, renal function test, urine routine examination, prothrombin time-activated partial thrombin time, bleeding time, clotting time, and transplant kidney ultrasonography with Doppler studies prior to allograft biopsy. The rise in creatinine from baseline to the time of biopsy was based on a comparison of the nadir creatinine within the past 6 months and last creatinine preceding or on the biopsy date.
Transplant biopsies were performed under ultrasound guidance with 16-18G needles and a spring-loaded biopsy gun after informed consent in the supine position by a trainee nephrologist. As per our protocol, all patients were kept under observation for 24 h in transplant unit after the procedure with strict bed rest and regular blood pressure monitoring.
Before discharge, repeat ultrasound examination was done to look for hematoma formation. Hematocrit drop of >3% prompted for repeated hematocrit and/or further evaluation for hemorrhage.
A major complication of a renal transplant biopsy was defined as the need for additional hospitalization time and/or an active intervention. This included hospital admission, transfusion of blood products, interventional radiology vascular procedure, surgical exploration, transplant removal, and/or death.
Biopsy reports were noted and were matched against clinical provisional diagnosis. Biopsy was reported as per the Banff criteria 2013. [8] We documented the change in treatment done by the treating nephrologist after biopsy report and assessed the utility of renal allograft biopsies to improve patients' outcome by carefully noting the detailed follow-up of patients with renal function test and urine examination.
Statistical analysis
The data were entered into an Excel spreadsheet and analyzed using the SPSS software (SPSS Inc., Chicago, IL, USA). Summary categorical statistics were expressed as number (percentage). Summary continuous statistics were expressed as mean ± standard deviation if normally distributed or median (interquartile range [IQR]) if not.
rEsults
Overall, 150 biopsies were performed in 117 patients in 5 years; 24 patients underwent procedure twice and 3 patients underwent thrice. All biopsies were indicated biopsies, and no protocol biopsy was performed. Mean age was 38.3 ± 11.6 years at the time of biopsy, with a male-to-female ratio of 92:25. The majority (n = 77 [65.81%]) of the patients had no known primary etiology for chronic kidney disease. Autosomal dominant polycystic kidney disease (7.69%) and diabetic nephropathy (7.69%) were the most common primary diseases, followed by immunoglobulin (Ig) A nephropathy (5.12%) [ Table 1 ].
One hundred and five (89.74%) patients received kidney from live donors (parents/sibling/spouse/paired donation/ABO incompatible) and 12 (10.25%) patients received from deceased donors. Most of the patients had 2 (29.52%) or 3 (26.66%) human leukocyte antigen mismatches, and majority (62.39%) received injection methylprednisolone (500 mg 2 doses with 1-g intraoperative dose) along with capsule tacrolimus (0.1 mg/kg) and mycophenolate sodium (720 mg bd) without any antibody induction. The majority of the patients were on triple immunosuppression in the form of prednisolone (10 mg/day) (100%) + capsule tacrolimus (97.43%) + mycophenolate sodium (96.58%) [ Table 1 ].
Median time from transplant to the first biopsy was 24 months (IQR: 2-61). Of 150 biopsies, 34 (22.66%) were performed within 15 days posttransplantation. Mean serum creatinine, mean rise in creatinine, and mean hemoglobin before biopsy were 2.4 ± 1.75 mg/dl, 1.62 ± 0.82 mg/dl, and 10.6 ± 0.76 g/dl, respectively.
Indication of renal allograft biopsy
Acute allograft dysfunction (54%) was the most common indication for which biopsy was performed; most patients had asymptomatic rise in creatinine (32.7%) (noticed on routine investigations), followed by proteinuria (17.33%). In the first 15 days posttransplantation, the most common indication was delayed graft function (15.33%) [ Table 2 ].
Adequacy of biopsy
One hundred and thirty-five (90%) biopsies were adequate, whereas 1 (0.66%) was marginal, 2 (1.33%) were inadequate, and 12 (8%) had no renal tissue.
Histological findings
For clinical diagnosis of acute allograft dysfunction, the most common histopathological finding was active antibody-mediated rejection (AAMR) in 20 (14.49%) patients, followed by acute calcineurin inhibitor toxicity in 18 (13.04%) patients and acute tubular necrosis in 14 (10.14%) patients. In the presence of chronic allograft dysfunction, the most common histopathological finding was chronic AMR in 18 (13.04%) biopsies, followed by recurrence of disease in 15 (10.86%). Least incidence was of posttransplant lymphoproliferative disorder (0.72%) [ Table 3 ].
Correlation with clinical diagnosis
Overall, in 84.66% of cases, histopathological diagnosis matched the clinical provisional diagnosis. Changes were made in treatment according to biopsy findings including reduction in tacrolimus doses (13.33%), switching to sirolimus from tacrolimus (1.3%), steroid pulses (20.6%), injection antithymocyte globulin (13.33%), and steroid pulse with intravenous Ig with plasmapheresis (15.86%).
Complications
The most common complication was gross hematuria (7.33%), followed by hematoma (3.33%) formation noted on 24 h postprocedure ultrasonography. Major complications occurred in 4.0% of the patients which included blood transfusion in 2.66%, 1 (0.06%) patient needed allograft removal, and 1 (0.06%) patient expired postprocedure [ Table 4 ].
disCussion
Renal allograft biopsy has been regarded as a gold standard for allograft dysfunction after vascular and surgical causes have been ruled out. There are very few published data regarding renal allograft biopsy from India.
In our study, we found that the most common indication for allograft biopsy was acute allograft dysfunction (81.17%) with asymptomatic rise in creatinine (32.66%) as the most common clinical presentation. Recently published data from eastern India showed a similar finding of asymptomatic rise of creatinine as the most common clinical presentation. [9] Only 8% of the biopsies had no tissue, whereas 90% of the biopsies were adequate. [8] This is comparable to other recently published studies which showed that 88% of transplant biopsies had >10 glomeruli. [10] However, in this study, [10] only 63% of biopsies were performed by fellow in comparison to our study where all biopsies were performed by nephrology residents (trainee fellow).
In our study, the most common pathological finding for acute allograft dysfunction was AAMR (14.49%). Various recently published studies showed comparable results with AAMR finding in 16.5%-24% of acute rejection biopsies. [11, 12] With better potent immunosuppression available in this era, the incidence of T-cell-mediated rejection has been controlled. AMR appears to be on the rise, likely secondary to changing trends in clinical practice, including selection of patients for transplantation with high risk and development of more effective combinations of immunosuppressive drugs against acute cellular rejection. Our finding is consistent with other studies published from India showing more incidences of AMR then T-cell mediated rejections. [13, 14] For chronic allograft dysfunction, the most common pathological finding was chronic rejection (chronic AMR + chronic AAMR). In a prospective study, the majority (63%) of the indication biopsy samples from renal allografts that failed after 12 months had evidence of chronic AMR. [15] Histopathological diagnosis matched clinical diagnosis in the majority of the patients (61.33%). This is in contrast to that of Al-Awwa et al. who reported a poor correlation between clinical and histological diagnoses. [16] However, treatment was modified in 64.10% of patients following renal biopsy.
The success of any procedure depends on diagnostic yield as well as safety. The major complication rate in our study was 4% (blood transfusion, surgical intervention, and death) which is comparable to other studies [ Table 5 ]. [10, 17] 
ConClusion
Renal allograft biopsy is a useful tool in the evaluation of allograft dysfunction and must be performed whenever needed. With current biopsy technique under real-time sonography, the major complication rate is less and it can be regarded as a safe procedure with excellent diagnostic yield.
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